United States Counsels Against Certiorari In Schizophrenia Treatment Patent Suit

Mealey's (December 13, 2019, 10:49 AM EST) -- WASHINGTON, D.C. — Although the U.S. government acknowledges that ambiguity exists as to the patentability of method-of-treatment patterns under Section 101 of the Patent Act, in a Dec. 6 amicus curiae brief the government suggests that the U.S. Supreme Court deny a petition for certiorari by the maker of a generic schizophrenia drug, stating that the present case did not provide an optimal vehicle to consider the matter because the Federal Circuit U.S. Court of Appeals reached the correct decision in the underlying patent dispute despite the existing confusion (Hikma Pharmaceuticals USA Inc., et al. v. Vanda Pharmaceuticals USA Inc., No. 18-817, U.S. Sup.)....